Idera Pharmaceuticals is a biopharmaceutical company focused on the clinical development and commercialization of drug candidates for both oncology and rare disease indications. Co.'s focus is on its Toll-like receptor (TLR) agonist, tilsotolimod (IMO-2125), for oncology. Co. is developing tilsotolimod, via intratumoral injection, for the treatment of anti-PD1 refractory metastatic melanoma in combination with ipilimumab, an anti-CTLA4 antibody marketed as Yervoy® by Bristol Myers Squibb Company (BMS). Co. is also evaluating intratumoral tilsotolimod in combination with nivolumab, an anti-PD1 antibody marketed as Opdivo® by BMS, and ipilimumab for the treatment of multiple solid tumors. The IDRA stock yearly return is shown above.
The yearly return on the IDRA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2014 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IDRA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|